等待開盤 05-22 09:30:00 美东时间
+0.050
+2.16%
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $4.
05-21 22:12
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over losses of $(0.19) per
05-12 21:06
Connect Biopharma reported Q1 2026 financial results with $46.0 million in cash and a $20.2 million private placement. Phase 2 Seabreeze STAT studies for asthma and COPD exacerbations continue as planned, with topline data expected mid-2026. Positive Phase 1 data for rademikibart showed rapid lung function improvements. The company is advancing its IL-4Rα-targeting antibody for inflammatory diseases, with a focus on acute asthma and COPD exacerba...
05-12 13:00
截至2026年4月27日(美国东部时间)收盘,康乃德生物医药(CNTB.US)报收于2.45美元/股,下跌2.78%,成交量14.22万股。
04-28 06:20
The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at 28 days, the rate of new exacerbations through 28 days, and the change from baseline in FEV1 following treatment of a
04-23 21:03
Turbo Energy涨24.26%;Robin Energy Ltd.涨23.44%;Indonesia Energy Corp Ltd.涨13.25%
04-02 13:01
PMGC Holdings Inc.涨-48.00%;System1 Inc涨-11.69%;中国循环能源涨-9.73%
04-02 08:10
今日重点评级关注:Maxim Group:上调Theriva Biologics评级至"买入",目标价1美元;HC Wainwright & Co.:维持Bicara Therapeutics"买入"评级,目标价从40美元升至42美元
04-01 16:34
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) by 10 percent. This is a 68.75 percent decrease over losses of $(0.16) per share
04-01 05:30
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –– Rademikibart was well tolerated with safety comparable
03-30 19:11